MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access pro
Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire Bioniz Therap
Bristol-Myers Squibb's rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease (GvHD), a serious complication of haematopoietic stem cell transpl
Less than a month after Kadmon Pharma launched its first product – Rezurock for a complication of organ transplants – the New York company has agreed to be bought by Sanofi in a $1.9 billio
The FDA has rejected Mesoblast’s Ryoncil cell therapy for children with graft versus host disease, despite a recommendation to approve from a panel of expert advisers.
Australian radiopharma developer Telix Pharma and US neuroscience specialist Rapport Therapeutics have become the latest biotechs to weigh in for initial public offerings
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.